Screening nucleotide and nucleoside analogues as potential inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase by the molecular docking method for the treatment of COVID-19

The COVID-19 pandemic triggering acute respiratory syndrome is a major global health concern. SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) enzyme regulating viral replication has been evaluated as potential therapeutic target for inhibition of the infection SARS-CoV-2. In this study, we ability drug inhibitors by using molecular docking in silico model. Lipinski’s rule Five was used to evaluate - like properties compound. Pharmacokinetic parameters compounds were assessed pkCSM tool. Based on previous publications, have collected 100 compounds. results exhibited that 18 RdRp inhibitory activity stronger than remdesivir reference showed 17 among had proprietary drug-likenesss. Compounds including novuridine, didanosine, sofosbuvir, puromycin, defibrotite, gemcitabine, and nikkomycins are most negative energies pharmacokinetic good absorption, not metabolised liver, excreted kidney may hepatotoxicity properties. Therefore, it necessary conduct vitro vivo assays developthese into drugs treatment